Business Update - approval of Alzheimers therapeutic
Filed with ASX · · 6 pages · English
Eisai Co., Ltd (Japan) and their development partner, Biogen Inc, have announced that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval for aducanumab (to be marketed as TM ADUHELM ) for the treatment of Alzheimer’s disease. A copy of the press release from Eisai Co. Ltd and Biogen Inc. is attached. The accelerated approval has been granted based on data from clinical tr
Earlier from Cogstate
- Investor Presentation
- Appendix 4C - quarterly
- FY21 Half Year Report
- FY21 Half Year Results Announcement
- FY21 Half Year Result Presentation
Later from Cogstate
- Loan Forgiven re US Governments Paycheck Protection Program
- Value of FY21 Clinical Trials Sales Contracts up 15%
- July 2021 Investor Presentation
- June quarter business update and cashflow report
- Quarterly Sales Contracts Executed To Date
Follow Cogstate into a list and get an email when it puts out news.
Follow Cogstate